| ACE | Angiotensin-converting enzyme |
| ACEI | Angiotensin-converting enzyme inhibitor |
| AngII | Angiotensin II |
| ARBs | Angiotensin II receptor blockers |
| CI | Confidence interval |
| CTCAE | Common Terminology Criteria for Adverse Events |
| CTLA-4 | Cytotoxic T-lymphocyte-associated protein 4 |
| ECOG | Eastern Cooperative Oncology Group |
| HR | Hazard ratio |
| ICI | Immune checkpoint inhibitor |
| ICIs | Immune checkpoint inhibitors |
| IL-6 | Interleukin-6 |
| irAE | Immune-related adverse event |
| irAEs | Immune-related adverse events |
| MDSCs | Myeloid-derived suppressor cells |
| NSCLC | Non-small cell lung cancer |
| OS | Overall survival |
| PD-1 | Programmed cell death protein 1 |
| PD-L1 | Programmed death-ligand 1 |
| PFS | Progression-free survival |
| RAS | Renin–angiotensin system |
| SCLC | Small cell lung cancer |
| SPSS | Statistical Package for the Social Sciences |
| TGF-β | Transforming growth factor-beta |
| TME | Tumor microenvironment |
| TNF-α | Tumor necrosis factor-alpha |